http://www.marketwatch.com/story/vyteris-expands-scientific-advisory-board-with-four-new-appointments-2010-07-13?reflink=MW_news_stmp
July 13, 2010, 9:00 a.m. EDT ·
Vyteris Expands Scientific Advisory Board With Four New Appointments
*** begin quote ***
FAIR LAWN, NJ, Jul 13, 2010 (MARKETWIRE via COMTEX) — Vyteris, Inc. /quotes/comstock/11k!vytr (VYTR 0.50, 0.00, 0.00%) , manufacturer of the first FDA-approved active patch transdermal drug delivery system, and a leader in active transdermal drug delivery technology, today announced the appointment of four new members to its Scientific Advisory Board (SAB). The new appointments enhance the range and depth of expertise of the SAB, which provides technical and strategic guidance for the company’s research, product development, and commercialization activities.
The new members of the SAB are: David Cohen, M.D., Robert Shorr, Ph.D., David Filer, Ph.D., and Michael Reidy, Ph.D. They join Russell Potts, Ph.D., who serves as Chairman of the SAB, and Richard Guy, Ph.D., who became the founding members of the SAB in 2008.
“These individuals are highly regarded thought leaders who bring to Vyteris a rich diversity of experience and expertise in drug delivery, dermatology, rheumatology, pain management, and bioscience generally. It is a pleasure to welcome them to our Scientific Advisory Board,” said Haro Hartounian, Ph.D., president and CEO of Vyteris. “We look forward to their contributions and insights as we continue evaluating partnering and development opportunities for our active transdermal drug delivery technology.”
The SAB now includes the following members:
{Extraneous Deleted}
– Michael Reidy, Ph.D., is currently Vice President, Research & Development, at Vyteris. Since joining Vyteris in 2004, he has played an instrumental role in leading and managing all internal and external research and product development activities. Prior to joining Vyteris, Dr. Reidy was Principal Scientist at Cygnus, Inc., and made critical contributions to the development and commercialization of the Glucowatch(R) Biographer, a transdermal iontophoretic system for non-invasive continuous glucose monitoring in patients with diabetes. Prior to that, Dr. Reidy held research positions at Dade-Behring and DuPont Medical Products, where he played a pivotal role in the design and commercial development of planar ion selective electrode and biosensor systems for in-vitro diagnostic product lines. Dr. Reidy started his career at DuPont’s Central Research and Development department after a post-doctoral fellowship at the Max-Planck Institute for Polymer Research in Mainz. Dr. Reidy holds a B.S. in chemistry from Manhattan College and a Ph.D. in organic chemistry from Polytechnic University (New York).
{Extraneous Deleted}
About Vyteris, Inc. Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite(R)) to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where the company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit us at www.vyteris.com.
{Extraneous Deleted}
SOURCE: Vyteris, Inc.
# – # – #
Reidy, Michael [MC????]
# # # # #
John,
There is no record of Michael Reidy in the directory,
Ed
McEneney Edward J. (MC1959)
[JR: Thanks, Ed. Much appreciated. Have to ask the "research staff" (i.e., the readership) to figure it out.]
# # # # #
John,
I believe Michael P. Reidy is a member of the class of 1984.
Ed
McEneney Edward J. (MC1959)
[JR: Thanks, Ed. Much appreciated.]
Reidy, Michael P. [MC1984]
# # # # #
